{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T07:26:24Z","timestamp":1792135584045,"version":"4.4.0"},"reference-count":47,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The therapeutic landscape in multiple myeloma (MM) has changed dramatically over the last 2 decades. With the introduction of novel immunotherapies, patients with MM can expect deeper responses, longer remissions, and improved overall survival. Since its approval by the US Food and Drug Administration in 2015, the monoclonal antibody specific for CD38, daratumumab, has been incorporated into both frontline and relapsed treatment regimens. Its role as a maintenance therapy is currently being explored. Subsequently, a variety of novel antibody therapeutics have evolved from the success of daratumumab, using similar concepts to target the malignant plasma cell clone. Noteworthy naked monoclonal antibodies include isatuximab, another agent directed against CD38, and elotuzumab, an agent directed against SLAM family member 7. Antibody-drug conjugates, complex molecules composed of an antibody tethered to a cytotoxic drug, target malignant cells and deliver a lethal payload. The first to market is belantamab mafodotin, which targets B-cell maturation antigen (BCMA) on malignant plasma cells and delivers a potent microtubule inhibitor, monomethyl auristatin F. Additionally, bispecific T-cell antibodies are in development that engage the immune system directly by simultaneously binding CD3 on T cells and a target epitope\u2014such as BCMA, G-protein coupled receptor family C group 5 member D (GPRC5d), and Fc receptor homologue 5 (FcRH5)\u2014on malignant cells. Currently, teclistamab, an anti-BCMA bispecific, is closest to approval for commercial use. In this review, we explore the evolving landscape of antibodies in the treatment of MM, including their role in frontline and relapse settings.<\/jats:p>","DOI":"10.1182\/hematology.2022000334","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T16:08:26Z","timestamp":1670602106000},"page":"163-172","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":29,"title":["Antibodies and bispecifics for multiple myeloma: effective effector therapy"],"prefix":"10.1182","volume":"2022","author":[{"given":"Christopher","family":"Cipkar","sequence":"first","affiliation":[{"name":"Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Trudel","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"issue":"5","key":"2022121313292734900_hem2022000334C1","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"issue":"5","key":"2022121313292734900_hem2022000334C2","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"2022121313292734900_hem2022000334C3","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1053\/j.seminoncol.2022.01.001","article-title":"Off-the-shelf\u201d immunotherapies for multiple myeloma","volume":"49","author":"Mohammed","year":"2022","journal-title":"Semin Oncol"},{"issue":"10","key":"2022121313292734900_hem2022000334C4","first-page":"624","article-title":"Daratumumab for the management of newly diagnosed and relapsed\/refractory multiple myeloma: current and emerging treatments","volume":"17","author":"Offidani","year":"2021","journal-title":"Front Oncol"},{"issue":"8","key":"2022121313292734900_hem2022000334C5","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"2022121313292734900_hem2022000334C6","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1038\/s41375-020-0711-6","article-title":"Daratumumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study","volume":"34","author":"Bahlis","year":"2020","journal-title":"Leukemia"},{"issue":"6","key":"2022121313292734900_hem2022000334C7","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"2022121313292734900_hem2022000334C8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(21)00579-9","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study","volume":"23","author":"Usmani","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10192","key":"2022121313292734900_hem2022000334C9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"2022121313292734900_hem2022000334C10","article-title":"Daratumumab (DARA) plus lenalidomide, bortezomib, and dexamethasone (RVd) in patients (Pts) with transplant-eligible newly diagnosed multiple myeloma (NDMM): final analysis of GRIFFIN after \u2265 1y follow up. Presented at: The International Myeloma Society 2022 Annual Meeting","author":"Sborov","year":"2022"},{"issue":"11","key":"2022121313292734900_hem2022000334C11","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomized, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10218","key":"2022121313292734900_hem2022000334C12","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet"},{"issue":"25","key":"2022121313292734900_hem2022000334C13","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6","key":"2022121313292734900_hem2022000334C14","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1001\/jamaoncol.2021.0611","article-title":"Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: the MANHATTAN nonrandomized clinical trial","volume":"7","author":"Landgren","year":"2021","journal-title":"JAMA Oncol"},{"issue":"10","key":"2022121313292734900_hem2022000334C15","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S1470-2045(21)00428-9","article-title":"Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"issue":"12","key":"2022121313292734900_hem2022000334C16","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1080\/14712598.2021.1841747","article-title":"Isatuximab for the treatment of relapsed\/refractory multiple myeloma","volume":"20","author":"Richardson","year":"2020","journal-title":"Expert Opin Biol Ther"},{"issue":"10214","key":"2022121313292734900_hem2022000334C17","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"issue":"10292","key":"2022121313292734900_hem2022000334C18","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"},{"issue":"suppl 1","key":"2022121313292734900_hem2022000334C19","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood-2021-145097","article-title":"Addition of isatuximab to lenalidomide, bortezomib and dexamethasone as induction therapy for newly-diagnosed, transplant-eligible multiple myeloma patients: the phase III GMMG-HD7 trial","volume":"138","author":"Goldschmidt","year":"2021","journal-title":"Blood"},{"issue":"20","key":"2022121313292734900_hem2022000334C20","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1002\/cncr.31680","article-title":"Elotuzumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial","volume":"124","author":"Dimopoulos","year":"2018","journal-title":"Cancer"},{"issue":"19","key":"2022121313292734900_hem2022000334C21","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"2022121313292734900_hem2022000334C22","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/S2352-3026(20)30354-9","article-title":"Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial","volume":"8","author":"Usmani","year":"2021","journal-title":"Lancet Haematol"},{"issue":"suppl 1","key":"2022121313292734900_hem2022000334C23","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1182\/blood-2021-147323","article-title":"Elotuzumab in combination with lenalidomide, bortezomib, dexamethasone and autologous transplantation for newly-diagnosed multiple myeloma: results from the randomized phase III GMMG-HD6 trial","volume":"138","author":"Goldschmidt","year":"2021","journal-title":"Blood"},{"issue":"6","key":"2022121313292734900_hem2022000334C24","doi-asserted-by":"crossref","first-page":"e403","DOI":"10.1016\/S2352-3026(22)00103-X","article-title":"Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial","volume":"9","author":"Dimopoulos","year":"2022","journal-title":"Lancet Haematol"},{"issue":"3","key":"2022121313292734900_hem2022000334C25","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s11523-018-0558-1","article-title":"Antibody-drug conjugates for the treatment of hematological malignancies: a comprehensive review","volume":"13","author":"Rossi","year":"2018","journal-title":"Target Oncol"},{"issue":"18","key":"2022121313292734900_hem2022000334C26","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10184088","volume":"10","author":"Kleber","year":"2021","journal-title":"J Clin Med"},{"issue":"20","key":"2022121313292734900_hem2022000334C27","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"issue":"22","key":"2022121313292734900_hem2022000334C28","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1002\/cncr.33809","article-title":"Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study","volume":"127","author":"Lonial","year":"2021","journal-title":"Cancer"},{"issue":"8","key":"2022121313292734900_hem2022000334C29","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1158\/0008-5472.CAN-17-3202","article-title":"Modulation of macropinocytosis-mediated internalization decreases ocular toxicity of antibody-drug conjugates","volume":"78","author":"Zhao","year":"2018","journal-title":"Cancer Res"},{"issue":"suppl 16","key":"2022121313292734900_hem2022000334C30","doi-asserted-by":"crossref","first-page":"8018","DOI":"10.1200\/JCO.2022.40.16_suppl.8018","article-title":"Safety and clinical activity of belantamab mafodotin with pembrolizumab in patients with relapsed\/refractory multiple myeloma (RRMM): DREAMM-4 Study [abstract]","author":"Suvannasankha","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2022121313292734900_hem2022000334C31","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1182\/blood-2021-152662","volume":"138","author":"Callander","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2022121313292734900_hem2022000334C32","first-page":"1419","volume":"138","author":"Popat","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"2022121313292734900_hem2022000334C33","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1182\/blood-2021-153315","article-title":"DREAMM-9: phase I study of belantamab mafodotin plus standard of care in patients with transplant-ineligible newly diagnosed multiple myeloma","volume":"138","author":"Usmani","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2022121313292734900_hem2022000334C34","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1182\/blood-2021-147101","article-title":"Part 1 results of a dose-finding study of belantamab mafodotin in combination with pomalidomide and dexamethasone for the treatment of relapsed\/refractory multiple myeloma (RRMM) [abstract]","volume":"138","author":"Trudel","year":"2021","journal-title":"Blood"},{"key":"2022121313292734900_hem2022000334C35","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/01.HS9.0000843604.69106.e8","article-title":"Safety and efficacy of belantamab mafodotin in combination with RD in newly diagnosed, transplant ineligible multiple myeloma patients: a phase 1\/2 study by the Hellenic Society of Hematology [abstract]","volume":"6","author":"Terpos","year":"2022","journal-title":"HemaSphere"},{"issue":"1","key":"2022121313292734900_hem2022000334C36","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41375-020-0834-9","article-title":"Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed\/refractory multiple myeloma","volume":"35","author":"Lee","year":"2021","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2022121313292734900_hem2022000334C37","first-page":"179","article-title":"Phase 1, first-in-human study of MEDI2228, a BCMA-targeted ADC in patients with relapsed\/refractory multiple myeloma [abstract]","volume":"138","author":"Kumar","year":"2020","journal-title":"Blood"},{"issue":"8","key":"2022121313292734900_hem2022000334C38","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1200\/JCO.19.02657","article-title":"Anti-B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma","volume":"38","author":"Topp","year":"2020","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2022121313292734900_hem2022000334C39","first-page":"181","article-title":"A phase 1 first in human (FIH) study of AMG 701, an anti-B-cell maturation antigen (BCMA) half-life extended (HLE) BiTE (bispecific T-cell engager) molecule, in relapsed\/refractory (RR) multiple myeloma (MM)","volume":"136","author":"Harrison","year":"2020","journal-title":"Blood"},{"issue":"6","key":"2022121313292734900_hem2022000334C40","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"suppl 16","key":"2022121313292734900_hem2022000334C41","doi-asserted-by":"crossref","first-page":"8014","DOI":"10.1200\/JCO.2022.40.16_suppl.8014","article-title":"Elranatamab, a BCMA-targeted T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma: updated results from MagnetisMM-1","volume":"40","author":"Jakubowiak","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2022121313292734900_hem2022000334C42","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1182\/blood-2021-144921","article-title":"Early, deep and durable responses and low rates of cytokine release syndrome with REGN5458, a BCMAxCD3 bispecific monoclonal antibody, in a phase 1\/2 first-in-human study in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"138","author":"Zonder","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2022121313292734900_hem2022000334C43","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/blood-2019-122895","article-title":"First clinical study of the B-cell maturation antigen (BCMA) 2\u200a+\u200a1 T cell engager (TCE) cc-93269 in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): interim results of a phase 1 multicenter trial","volume":"134","author":"Costa","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2022121313292734900_hem2022000334C44","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1182\/blood-2021-150757","article-title":"A first-in-human study of TNB-383B, a BCMA x CD3 $$","volume":"138","author":"Kumar","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2022121313292734900_hem2022000334C45","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood-2021-147983","article-title":"Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study","volume":"138","author":"Trudel","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2022121313292734900_hem2022000334C46","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/blood-2021-146868","article-title":"Updated phase 1, results from monumental: first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed and\/or refractory multiple myeloma (RRMM)","volume":"138","author":"Krishnan","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2022121313292734900_hem2022000334C47","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1182\/blood-2021-151585","article-title":"Clinical outcomes of relapsed\/refractory multiple myeloma patients following treatment with bispecific antibodies (BiAbs)","volume":"138","author":"Mouhieddine","year":"2021","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/163\/2023029\/163cipkar.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/163\/2023029\/163cipkar.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T13:33:20Z","timestamp":1670938400000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2022\/1\/163\/493531\/Antibodies-and-bispecifics-for-multiple-myeloma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12,9]]},"published-print":{"date-parts":[[2022,12,9]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2022000334","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,9]]},"published":{"date-parts":[[2022,12,9]]}}}